Prioritization of research addressing management strategies for ductal carcinoma in situ
- PMID: 24567146
- DOI: 10.7326/M13-2548
Prioritization of research addressing management strategies for ductal carcinoma in situ
Abstract
Ductal carcinoma in situ is a common finding in women having mammography screening, and there is considerable uncertainty about the balance of harms and benefits of different management options. This article outlines the process for developing a prioritized research agenda for the Patient-Centered Outcomes Research Institute as informed by a diverse group of stakeholders on the management of ductal carcinoma in situ. Evidence gaps were identified by reviewing existing literature and engaging diverse stakeholders to refine these gaps. Stakeholders ranked evidence gaps by importance from their perspectives using a forced-ranking prioritization method. PubMed was searched for relevant recent studies, and ClinicalTrials.gov was searched for relevant ongoing trials for the 10 highest-ranked evidence gaps. Strengths and limitations of different study designs were assessed to address gaps. Stakeholders prioritized evidence gaps related to incorporation of patient-centered outcomes into future research, development of better methods to predict risk for invasive cancer, evaluation of a strategy of active surveillance, and testing of decision-making tools. The degree to which prioritized evidence gaps may have already been addressed is uncertain because a comprehensive systematic review has not been done.
Similar articles
-
Prioritization of research addressing antipsychotics for adolescents and young adults with bipolar disorder.Ann Intern Med. 2014 Apr 1;160(7):492-8. doi: 10.7326/M13-2549. Ann Intern Med. 2014. PMID: 24567115
-
Future Research Prioritization: Implantable Cardioverter-Defibrillator Therapy in Older Patients.J Gen Intern Med. 2015 Dec;30(12):1812-20. doi: 10.1007/s11606-015-3411-6. J Gen Intern Med. 2015. PMID: 26014894 Free PMC article.
-
Setting a research agenda for ductal carcinoma in situ that meets the current need for change.Ann Intern Med. 2014 Apr 1;160(7):511-2. doi: 10.7326/M14-0435. Ann Intern Med. 2014. PMID: 24566896 No abstract available.
-
Treatment of ductal carcinoma in situ: an uncertain harm-benefit balance.Prescrire Int. 2013 Dec;22(144):298-303. Prescrire Int. 2013. PMID: 24600734 Review.
-
The management of ductal carcinoma in situ: current controversies and future directions.Clin Oncol (R Coll Radiol). 2013 May;25(5):275-82. doi: 10.1016/j.clon.2013.01.007. Epub 2013 Feb 28. Clin Oncol (R Coll Radiol). 2013. PMID: 23453783 Review.
Cited by
-
Defining precancer: a grand challenge for the cancer community.Nat Rev Cancer. 2024 Nov;24(11):792-809. doi: 10.1038/s41568-024-00744-0. Epub 2024 Oct 1. Nat Rev Cancer. 2024. PMID: 39354069 Review.
-
The effects of contemporary treatment of DCIS on the risk of developing an ipsilateral invasive Breast cancer (iIBC) in the Dutch population.Breast Cancer Res Treat. 2024 Feb;204(1):61-68. doi: 10.1007/s10549-023-07168-8. Epub 2023 Nov 14. Breast Cancer Res Treat. 2024. PMID: 37964135 Free PMC article.
-
Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study.BMJ. 2023 Oct 30;383:e076022. doi: 10.1136/bmj-2023-076022. BMJ. 2023. PMID: 37903527 Free PMC article.
-
Active surveillance versus treatment in low-risk DCIS: Women's preferences in the LORD-trial.Eur J Cancer. 2023 Oct;192:113276. doi: 10.1016/j.ejca.2023.113276. Epub 2023 Aug 4. Eur J Cancer. 2023. PMID: 37657228 Free PMC article.
-
Is palpable DCIS more aggressive than screen-detected DCIS?Surg Open Sci. 2022 Dec 12;11:83-87. doi: 10.1016/j.sopen.2022.12.002. eCollection 2023 Jan. Surg Open Sci. 2022. PMID: 36589700 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical